Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.

Fontana P, Cattaneo M, Combescure C, Reny JL.

J Am Heart Assoc. 2013 Mar 27;2(2):e000131. doi: 10.1161/JAHA.112.000131.

2.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

3.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
4.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29.

PMID:
22464343
5.

Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.

Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yang YJ, Yuan JQ.

Chin Med J (Engl). 2013 Mar;126(6):1069-75.

6.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Epub 2011 Dec 30. Review.

PMID:
22207144
7.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L.

Am J Cardiol. 2009 Dec 1;104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015.

PMID:
19932784
8.
9.

Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.

Smock KJ, Saunders PJ, Rodgers GM, Johari V.

Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Epub 2011 Aug 2. Review.

10.

Genetics of platelet inhibitor treatment.

Trenk D, Hochholzer W.

Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230. Review.

11.

Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.

Circ Cardiovasc Interv. 2010 Oct;3(5):450-9. doi: 10.1161/CIRCINTERVENTIONS.110.949859. Epub 2010 Sep 7.

12.

The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.

Namazi S, Kojuri J, Khalili A, Azarpira N.

Biochem Pharmacol. 2012 Apr 1;83(7):903-8. doi: 10.1016/j.bcp.2012.01.003. Epub 2012 Jan 12.

PMID:
22265638
13.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
14.

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM.

Heart. 2011 Aug;97(15):1239-44. doi: 10.1136/hrt.2010.220509. Epub 2011 May 31.

PMID:
21628721
15.

Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.

Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, Park HI, Chang K.

Biomed Res Int. 2013;2013:154073. doi: 10.1155/2013/154073. Epub 2013 Mar 28.

16.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
17.

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients.

Li Y, Tang HL, Hu YF, Xie HG.

J Thromb Haemost. 2012 Feb;10(2):199-206. doi: 10.1111/j.1538-7836.2011.04570.x. Review.

PMID:
22123356
18.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
19.

CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.

Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D.

Thromb Res. 2012 Apr;129(4):441-6. doi: 10.1016/j.thromres.2011.07.022. Epub 2011 Aug 9.

PMID:
21831410
20.

Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.

Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA.

Circ Cardiovasc Interv. 2011 Dec 1;4(6):585-94. doi: 10.1161/CIRCINTERVENTIONS.111.962555. Epub 2011 Nov 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk